Literature DB >> 21243428

Effect of HFE variants on sphingolipid expression by SH-SY5Y human neuroblastoma cells.

F Ali-Rahmani1, J A Hengst, J R Connor, C-L Schengrund.   

Abstract

C282Y and H63D are two common variants of the hemochromatosis protein HFE. SH-SY5Y human neuroblastoma cells stably transfected to express either wild type HFE (WT-HFE), or the C282Y or H63D allele were analyzed for effect of expression of the mutant proteins on transcription of 14 enzymes involved in sphingolipid metabolism. Cells expressing the C282Y variant showed significant increases (>2-fold) in transcription of five genes and decreases in two compared to that seen for cells expressing WT-HFE, while cells expressing the H63D variant showed an elevation in transcription of one gene and a decrease in two. These changes were seen as alterations in ganglioside composition, cell surface binding by the binding subunit of cholera toxin, expression of sphingosine-kinase-1 and synthesis of sphingosine-1-phosphate. These changes may explain why C282Y-HFE is a risk factor for colon and breast cancer and possibly protective against Alzheimer's disease while H63D-HFE is a risk factor for neurodegenerative diseases.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21243428     DOI: 10.1007/s11064-011-0403-8

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  54 in total

1.  Assembly of hereditary amyloid beta-protein variants in the presence of favorable gangliosides.

Authors:  Naoki Yamamoto; Yoshio Hirabayashi; Masakuni Amari; Haruyasu Yamaguchi; Galina Romanov; William E Van Nostrand; Katsuhiko Yanagisawa
Journal:  FEBS Lett       Date:  2005-04-11       Impact factor: 4.124

2.  Cell membrane GM1 ganglioside is a functional coreceptor for fibroblast growth factor 2.

Authors:  Marco Rusnati; Chiara Urbinati; Elena Tanghetti; Patrizia Dell'Era; Hugues Lortat-Jacob; Marco Presta
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-26       Impact factor: 11.205

3.  Ganglioside designation.

Authors:  L Svennerholm
Journal:  Adv Exp Med Biol       Date:  1980       Impact factor: 2.622

4.  Altered expression of the D1.1 ganglioside in the cerebellum of the Weaver mouse.

Authors:  S R Johnstone; W B Stallcup
Journal:  J Neurochem       Date:  1988-11       Impact factor: 5.372

Review 5.  Sphingolipid/cholesterol regulation of neurotransmitter receptor conformation and function.

Authors:  Jacques Fantini; Francisco J Barrantes
Journal:  Biochim Biophys Acta       Date:  2009-09-03

6.  Efficacy of interleukin-13 receptor-targeted liposomal doxorubicin in the intracranial brain tumor model.

Authors:  Achuthamangalam B Madhankumar; Becky Slagle-Webb; Xinsheng Wang; Qing X Yang; David A Antonetti; Patti A Miller; Jonas M Sheehan; James R Connor
Journal:  Mol Cancer Ther       Date:  2009-03-10       Impact factor: 6.261

7.  Membrane raft disruption promotes axonogenesis in n2a neuroblastoma cells.

Authors:  Kimberly A Petro; Cara-Lynne Schengrund
Journal:  Neurochem Res       Date:  2008-02-29       Impact factor: 3.996

8.  Gangliosides inhibit platelet-derived growth factor-stimulated receptor dimerization in human glioma U-1242MG and Swiss 3T3 cells.

Authors:  J Van Brocklyn; E G Bremer; A J Yates
Journal:  J Neurochem       Date:  1993-07       Impact factor: 5.372

9.  Microarray analysis of altered sphingolipid metabolism reveals prognostic significance of sphingosine kinase 1 in breast cancer.

Authors:  Eugen Ruckhäberle; Achim Rody; Knut Engels; Regine Gaetje; Gunter von Minckwitz; Susanne Schiffmann; Sabine Grösch; Gerd Geisslinger; Uwe Holtrich; Thomas Karn; Manfred Kaufmann
Journal:  Breast Cancer Res Treat       Date:  2007-12-04       Impact factor: 4.872

10.  Increased incidence of the Hfe mutation in amyotrophic lateral sclerosis and related cellular consequences.

Authors:  Xin-Sheng Wang; Sang Lee; Zachary Simmons; Philip Boyer; Kevin Scott; Wenlei Liu; James Connor
Journal:  J Neurol Sci       Date:  2004-12-15       Impact factor: 3.181

View more
  4 in total

1.  Etoposide-loaded immunoliposomes as active targeting agents for GD2-positive malignancies.

Authors:  Brandon S Brown; Tariq Patanam; Keyan Mobli; Christian Celia; Peter E Zage; Andrew J Bean; Ennio Tasciotti
Journal:  Cancer Biol Ther       Date:  2014-04-22       Impact factor: 4.742

2.  Cholesterol, GM1, and autism.

Authors:  Cara-Lynne Schengrund; Fatima Ali-Rahmani; Jeanette C Ramer
Journal:  Neurochem Res       Date:  2012-01-18       Impact factor: 3.996

3.  C282Y-HFE gene variant affects cholesterol metabolism in human neuroblastoma cells.

Authors:  Fatima Ali-Rahmani; Michael A Huang; C-L Schengrund; James R Connor; Sang Y Lee
Journal:  PLoS One       Date:  2014-02-12       Impact factor: 3.240

Review 4.  HFE gene variants, iron, and lipids: a novel connection in Alzheimer's disease.

Authors:  Fatima Ali-Rahmani; Cara-Lynne Schengrund; James R Connor
Journal:  Front Pharmacol       Date:  2014-07-08       Impact factor: 5.810

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.